Thompson Investment Management Inc. Sells 60 Shares of Danaher Co. (NYSE:DHR)

Thompson Investment Management Inc. reduced its stake in shares of Danaher Co. (NYSE:DHR) by 26.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171 shares of the conglomerate’s stock after selling 60 shares during the quarter. Thompson Investment Management Inc.’s holdings in Danaher were worth $41,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Clarus Wealth Advisors boosted its holdings in Danaher by 8.1% in the second quarter. Clarus Wealth Advisors now owns 961 shares of the conglomerate’s stock valued at $224,000 after acquiring an additional 72 shares during the last quarter. AE Wealth Management LLC lifted its position in Danaher by 8.0% during the 2nd quarter. AE Wealth Management LLC now owns 34,706 shares of the conglomerate’s stock valued at $8,329,000 after purchasing an additional 2,580 shares during the period. Appleton Partners Inc. MA boosted its stake in shares of Danaher by 251.6% in the 2nd quarter. Appleton Partners Inc. MA now owns 34,061 shares of the conglomerate’s stock valued at $8,175,000 after purchasing an additional 24,373 shares during the last quarter. DNB Asset Management AS grew its position in shares of Danaher by 26.6% during the 2nd quarter. DNB Asset Management AS now owns 287,482 shares of the conglomerate’s stock worth $68,996,000 after buying an additional 60,327 shares during the period. Finally, Moody National Bank Trust Division grew its position in shares of Danaher by 1.3% during the 2nd quarter. Moody National Bank Trust Division now owns 13,726 shares of the conglomerate’s stock worth $3,294,000 after buying an additional 172 shares during the period. Institutional investors and hedge funds own 76.71% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, EVP Joakim Weidemanis sold 22,439 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $263.42, for a total transaction of $5,910,881.38. Following the completion of the transaction, the executive vice president now owns 88,689 shares of the company’s stock, valued at approximately $23,362,456.38. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Danaher news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of Danaher stock in a transaction on Monday, August 21st. The shares were sold at an average price of $250.54, for a total value of $147,818.60. Following the sale, the senior vice president now directly owns 6,939 shares in the company, valued at approximately $1,738,497.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joakim Weidemanis sold 22,439 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $263.42, for a total transaction of $5,910,881.38. Following the transaction, the executive vice president now owns 88,689 shares of the company’s stock, valued at $23,362,456.38. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,922 shares of company stock valued at $12,552,233. 11.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DHR shares. Raymond James raised their price objective on shares of Danaher from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Wednesday, July 26th. StockNews.com assumed coverage on Danaher in a research report on Tuesday, September 12th. They issued a “hold” rating on the stock. Barclays upped their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Tuesday, July 25th. Bank of America raised their target price on Danaher from $250.00 to $280.00 in a report on Wednesday, July 26th. Finally, Royal Bank of Canada boosted their target price on Danaher from $260.00 to $292.00 in a research report on Wednesday, July 26th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $289.79.

Danaher Stock Performance

Shares of DHR opened at $255.25 on Friday. The firm has a market cap of $188.46 billion, a P/E ratio of 29.96, a PEG ratio of 2.72 and a beta of 0.80. Danaher Co. has a twelve month low of $221.22 and a twelve month high of $283.63. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.70 and a current ratio of 2.08. The firm’s 50 day moving average price is $253.41 and its two-hundred day moving average price is $245.09.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 25th. The conglomerate reported $2.05 EPS for the quarter, beating the consensus estimate of $2.01 by $0.04. The business had revenue of $7.16 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Danaher had a net margin of 20.95% and a return on equity of 15.03%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.76 EPS. On average, analysts forecast that Danaher Co. will post 8.84 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Thursday, October 12th will be issued a dividend of $0.27 per share. The ex-dividend date is Wednesday, October 11th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. Danaher’s payout ratio is presently 12.68%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.